Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
SFC 50/100 Mcg/Day First	GW815SF (SFC; Salmeterol/Fluticasone propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily in first intervention period and SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg + FP (Fluticasone Propionate) DPI 50 mcg twice daily in second intervention period (after washout period).
SLM 50 Mcg + FP 100 Mcg/Day First	SLM (Salmeterol) DPI (Dry Powder Inhaler) 25 mcg + FP (Fluticasone Propionate) DPI 50 mcg twice daily in first intervention period and GW815SF (SFC; Salmeterol/Fluticasone Propionate combination) HFA (Hydro Fluoro Alkane) MDI (Metered Dose Inhaler) 25/50 mcg twice daily in second intervention period (after washout period).

Participant Flow for 4 periods

	SFC 50/100 Mcg/Day First	SLM 50 Mcg + FP 100 Mcg/Day First
STARTED	26	25
COMPLETED	26	25
NOT COMPLETED	0	0

	SFC 50/100 Mcg/Day First	SLM 50 Mcg + FP 100 Mcg/Day First
STARTED	26	25
COMPLETED	25	25
NOT COMPLETED	1	0
Withdrawal by Subject	1	0

	SFC 50/100 Mcg/Day First	SLM 50 Mcg + FP 100 Mcg/Day First
STARTED	25	25
COMPLETED	25	25
NOT COMPLETED	0	0

	SFC 50/100 Mcg/Day First	SLM 50 Mcg + FP 100 Mcg/Day First
STARTED	50	0
COMPLETED	50	0
NOT COMPLETED	0	0

Reporting Groups

	Description
Overall Study Population	Randomized Population

Baseline Measures

	Overall Study Population
Number of Participants   [units: participants]	51
Age   [units: Years] Mean ± Standard Deviation	8.3 ± 2.41
Gender   [units: participants]
Female	17
Male	34
Race/Ethnicity, Customized   [units: Participants]
Asian-Japanese Heritage	51
Region of Enrollment   [units: participants]
Japan	51

1.  Primary:

Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods   [ Crossover Period Weeks 1-4, and 7-10 ]

2.  Secondary:

Adjusted Mean Change From Baseline in Percent Predicted Morning PEF(%) During the 4-week Treatment Periods   [ Crossover Period Weeks 1-4, 7-10 ]

3.  Secondary:

Adjusted Mean Change From Baseline in Percent Personal Best Morning PEF(%) During the 4-week Treatment Periods   [ Crossover Period weeks 1-4, 7-10 ]

4.  Secondary:

Adjusted Mean Change From Baseline in Evening PEF During the 4-week Treatment Periods   [ Crossover Period weeks 1-4, 7-10 ]

5.  Secondary:

Adjusted Mean Change From Baseline of Circadian Variation in Morning PEF(%) During the 4-week Treatment Periods   [ Crossover Period Weeks 1-4, 7-10 ]

6.  Secondary:

Percentage of Subjects With Symptom-Free Nights & Days   [ Crossover Period Week 1-4, 7-10 ]

7.  Secondary:

Percentage of Subjects With Rescue Medication-Free Nights and Days   [ Crossover Period Weeks 1-4, 7-10 ]

8.  Secondary:

Adjusted Mean Change From Baseline in Morning PEF During the 20-week Extension Treatment Period   [ Extension Period Weeks 11-30 ]

9.  Secondary:

Adjusted Mean Change From Baseline in Percent Predicted Morning PEF(%) During the 20-Week Extension Treatment Period   [ Extension Period weeks 11-30 ]

10.  Secondary:

Adjusted Mean Change From Baseline in Percent Personal Best Morning PEF(%) During the 20-week Extension Treatment Period   [ Extension Period weeks 11-30 ]

11.  Secondary:

Adjusted Mean Change From Baseline in Evening PEF During the 20-week Extension Treatment Period   [ Extension Period weeks 11-30 ]

12.  Secondary:

Adjusted Mean Change From Baseline of Circadian Variation in PEF(%) During the 20-Week Extension Treatment Period   [ Extension Period weeks 11-30 ]

13.  Secondary:

Percentage of Subjects With Symptom-Free Nights & Days After 20 Weeks of Treatment   [ Extension Period Weeks 11-30 ]

14.  Secondary:

Percentage of Subjects With Rescue Medication-Free Nights & Days After 20 Weeks of Treatment   [ Extension Period Weeks 11-30 ]